MoonLake, Stride, CarMax, and Jamf Face Fraud Investigations Amid Investor Concerns

2025-11-09 companies

New York, Sunday, 9 November 2025.
MoonLake Immunotherapeutics and other companies are under fraud investigation, highlighting corporate governance issues. MoonLake’s stock plummeted nearly 90% following failed trial revelations. Investors face deadlines to join lawsuits.

MoonLake Immunotherapeutics: A Deepening Crisis

MoonLake Immunotherapeutics (NASDAQ: MLTX) finds itself at the center of a storm of allegations following the revelation of its Phase 3 trial results for its drug candidate, sonelokimab (SLK). The trial, which was expected to demonstrate SLK’s superiority over existing treatments, instead delivered disappointing results, leading to a dramatic 90% drop in the company’s stock price from $61.99 to $6.24 per share on September 29, 2025 [1][3][5][6]. This decline has prompted a series of class action lawsuits filed by investors who allege that the company misled the market about the drug’s efficacy [1][3].

Legal Repercussions and Deadlines for Investors

The legal landscape is becoming increasingly complex for MoonLake as multiple law firms, including BFA Law and the Schall Law Firm, urge investors to come forward. The deadline for participating in the class action lawsuit is December 15, 2025, for those affected [1][5][6]. The lawsuits allege violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, asserting that MoonLake’s senior executives made false statements that misled investors about SLK’s clinical benefits [1][5].

Stride, Inc.: Missteps in Strategy and Execution

Stride, Inc. (NYSE: LRN), an education technology company, is also under scrutiny for potential securities fraud. The firm had claimed record demand for its products, only to disclose later that platform upgrades had been poorly executed, leading to a significant drop in enrollment numbers and a 54% drop in stock price from $153.53 to $70.05 per share in late October 2025 [2]. The law firm Bleichmar Fonti & Auld LLP is investigating the allegations, with investors encouraged to participate in the ongoing legal processes [2].

CarMax, Inc. and Jamf Holding Corp.: Governance in Question

CarMax, Inc. (NYSE: KMX) has faced its own set of challenges after announcing disappointing financial results and the sudden departure of its CEO, leading to a 24% drop in its stock price on November 6, 2025 [3]. Meanwhile, Jamf Holding Corp. (NASDAQ: JAMF) is being investigated for potential breaches of fiduciary duty related to a take-private transaction, raising concerns about conflicts of interest and governance practices [4]. Investors in both companies are urged to contact BFA Law to explore their legal options [3][4].

Sources

fraud investigation investor rights